1. Home
  2. GBIO vs AERT Comparison

GBIO vs AERT Comparison

Compare GBIO & AERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • AERT
  • Stock Information
  • Founded
  • GBIO 2016
  • AERT 2012
  • Country
  • GBIO United States
  • AERT Singapore
  • Employees
  • GBIO 115
  • AERT N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • AERT Professional Services
  • Sector
  • GBIO Health Care
  • AERT Consumer Discretionary
  • Exchange
  • GBIO Nasdaq
  • AERT Nasdaq
  • Market Cap
  • GBIO 29.2M
  • AERT 25.4M
  • IPO Year
  • GBIO 2020
  • AERT N/A
  • Fundamental
  • Price
  • GBIO $0.36
  • AERT $0.63
  • Analyst Decision
  • GBIO Strong Buy
  • AERT
  • Analyst Count
  • GBIO 4
  • AERT 0
  • Target Price
  • GBIO $7.33
  • AERT N/A
  • AVG Volume (30 Days)
  • GBIO 493.7K
  • AERT 39.8K
  • Earning Date
  • GBIO 05-07-2025
  • AERT 05-20-2025
  • Dividend Yield
  • GBIO N/A
  • AERT N/A
  • EPS Growth
  • GBIO N/A
  • AERT N/A
  • EPS
  • GBIO N/A
  • AERT 0.47
  • Revenue
  • GBIO $24,556,000.00
  • AERT $70,851,000.00
  • Revenue This Year
  • GBIO N/A
  • AERT N/A
  • Revenue Next Year
  • GBIO $10.90
  • AERT N/A
  • P/E Ratio
  • GBIO N/A
  • AERT $1.36
  • Revenue Growth
  • GBIO 146.47
  • AERT 4.38
  • 52 Week Low
  • GBIO $0.32
  • AERT $0.46
  • 52 Week High
  • GBIO $4.34
  • AERT $2.93
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 39.03
  • AERT 43.62
  • Support Level
  • GBIO $0.36
  • AERT $0.61
  • Resistance Level
  • GBIO $0.41
  • AERT $0.68
  • Average True Range (ATR)
  • GBIO 0.04
  • AERT 0.06
  • MACD
  • GBIO -0.00
  • AERT -0.01
  • Stochastic Oscillator
  • GBIO 9.09
  • AERT 26.89

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About AERT Aeries Technology Inc.

Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.

Share on Social Networks: